

| | | | | | | | | | | | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| | | | | | | | | | | | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|

School of Medical and Allied Sciences

Master of Pharmacy in Pharmacology

Mid Term Examination - May 2024

Duration : 90 Minutes

Max Marks : 30

Sem II - MPL204T - Clinical Research and PharmacovigilanceGeneral Instructions*Answer to the specific question asked**Draw neat, labelled diagrams wherever necessary**Approved data hand books are allowed subject to verification by the Invigilator*

- 1) Who are the members of Human subjects review board. K1 (2)
- 2) Outline the investigator play in the Ethics Committee review of a study K2 (2)
- 3) Classify the advantages of Phase - IV surveillance in clinical trial. K2 (2)
- 4) What are the responsibility and the authority IRB? K1 (2)
- 5) Explain the observations done in Phase-II of a clinical trial. K2 (2)
- 6) Identify all the requirements and content of informed consent. K3 (5)

- 7) Compare the members of ethics committee with compensation rules and Consent process. K4 (5)

OR

Compare RCT and NonRCT study designs in detail. K4 (5)

- 8) Determine the origin and activities of international conference on harmonization K5 (10)

OR

Determine the roles and responsibilities of Investigator, study coordinator, sponsor in detail. K5 (10)